Adamant Biomedical Investments’s AbbVie ABBV Stock Holding History

Adamant Biomedical Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$3.93M	Buy	+60,000	New	+$3.78M	0.94%	40

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Adamant Biomedical Investments's ABBV Position: Q4 2014 in Review

Adamant Biomedical Investments opened a new position in AbbVie (ABBV) in Q4 2014: 60,000 shares worth $3.93M. The stake represents 0.94% of the portfolio and ranks #40 among its holdings.

1,604 funds tracked by Wall St. Rank hold ABBV as of Q4 2014.

Adamant Biomedical Investments held 60,000 shares of AbbVie worth $3.93M as of Q4 2014.
AbbVie was a new Adamant Biomedical Investments position in Q4 2014.
AbbVie made up 0.94% of Adamant Biomedical Investments's portfolio in Q4 2014, its #40 holding.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.